rechtfertigen Rassel Im Wesentlichen laura coates rheumatology Farn Erfassung Möwe
PDF) What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study of 424 patients
Remission in Psoriatic Arthritis - YouTube
Reimagining the standard of care in Psoriatic Arthritis and Axial Spondyloarthritis - European Medical Journal
Family raises money for Psoriatic Arthritis research in Oxford — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
HealthPad - Contact
Laura Coates's Profile | CNN, SiriusXM Journalist | Muck Rack
Expanding psoriatic arthritis research at Oxford — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
Guidelines for the treatment of psoriatic arthritis with biologics
One of the few strategy trials in PsA': CONTROL sheds light on escalation, biologic use
Laura Coates, Lecturer - eMedEvents
Psoriatic Arthritis: Diagnosis and treatment - The Psoriasis Geek
ACR 2019 | The COAST-X trial | Ixekizumab in nonradiographic axial spondyloarthritis | Laura Coates | rheumatology.medicinematters.com
Laura Coates - Senior Clinical Research Fellow - University of Oxford | LinkedIn
Selecting Biologics in Active Psoriatic Arthritis
PDF) Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity
PDF) Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs
Dr. Laura Coates, MD – Cleveland, OH | Internal Medicine
ACR 2019 | THE SPIRIT-P3 study | Ixekizumab withdrawal in psoriatic arthritis | Laura Coates | rheumatology.medicinematters.com
Study Title: Optimising Psoriatic Arthritis Therapy with Immunological Methods to Increase Standard Evaluation Internal Referen
British Society for Rheumatology | London
ACR Highlights in PsA: Discussion with Professor Laura Coates - YouTube
Psoriatic arthritis trials should seek deeper remission states, end placebo controls